Ebbo Mikael, Patient Matthieu, Grados Aurelie, Groh Matthieu, Desblaches Julien, Hachulla Eric, Saadoun David, Audia Sylvain, Rigolet Aude, Terrier Benjamin, Perlat Antoinette, Guillaud Constance, Renou Frederic, Bernit Emmanuelle, Costedoat-Chalumeau Nathalie, Harlé Jean-Robert, Schleinitz Nicolas
Médecine Interne, Groupe Hospitalier Timone, AP-HM, Aix-Marseille Université, Marseille Médecine Interne, Hopital Cochin, Université Paris-Descartes, Paris Médecine Interne, Centre hospitalier de Pau, Pau CHRU-Hôpital Claude Huriez, Université de Lille, Lille Médecine Interne, Groupe hospitalier Pitie Salpêtrière AP-HP, Université Pierre et Marie Curie, Paris Médecine interne, CHU le Bocage, Université de Bourgogne, Dijon Médecine Interne, CHU Rennes, Rennes Médecine interne, CHU Mondor, Créteil CHG Saint Denis de la Réunion, Réunion, France.
Medicine (Baltimore). 2017 Mar;96(10):e6205. doi: 10.1097/MD.0000000000006205.
IgG4-related disease (IgG4-RD) is characterized by variable tissue or organ involvements sharing common pathological findings. Orbital or orbital adnexa involvement of the disease has been reported in a few case series. The aim of our study was to characterize and analyze ophthalmic manifestations from a nationwide French case-series.Patients with IgG4-RD and orbital or orbital adnexa involvement included in the French multicentric IgG4-RD case-registry were identified. Only patients fulfilling "modified" comprehensive diagnostic criteria with pathological documentation were retained for the study. Clinical, biological, pathological, radiological findings and data regarding the response to treatment were retrospectively analyzed.According to our data registry, the frequency of IgG4-related ophthalmic disease (IgG4-ROD) was 17%. Mean age at diagnosis was 55.1 ± 7.1 years with a male/female ratio of 2.2. The 19 cases of IgG4-ROD consisted of lacrimal gland (68.4%), soft tissue (57.9%), extra-ocular muscles (36.8%), palpebral (21.1%), optical nerve (10.5%), orbital bone (10.5%), and mononeuritis (V1 and/or V2, 10.5%) involvements. IgG4-ROD was bilateral in 57.9% of cases. Extra-ophthalmic manifestations were reported in 78.9% of cases. All patients responded to prednisone but two-thirds of patients relapsed within a mean (SD) of 9.8 (3.5) months and 72.2% required long-term glucocorticoids and/or immunosuppressive agents. Eight patients were treated by rituximab with a favorable response in 87.5% of cases.Lacrimal involvement is the most frequent ophthalmic manifestation of IgG4-RD and is frequently associated with extra-orbital manifestations. Despite initial favorable response to steroids, the long-term management of relapsing patients needs to be improved.
IgG4相关性疾病(IgG4-RD)的特征是不同组织或器官受累并具有共同的病理表现。少数病例系列报道了该疾病累及眼眶或眶周附件。我们研究的目的是对来自法国全国性病例系列的眼部表现进行特征描述和分析。
确定纳入法国多中心IgG4-RD病例登记处的IgG4-RD且累及眼眶或眶周附件的患者。本研究仅保留符合“改良”综合诊断标准并有病理记录的患者。对临床、生物学、病理、影像学检查结果以及治疗反应的数据进行回顾性分析。
根据我们的数据登记,IgG4相关性眼病(IgG4-ROD)的发生率为17%。诊断时的平均年龄为55.1±7.1岁,男女比例为2.2。19例IgG4-ROD患者包括泪腺受累(68.4%)、软组织受累(57.9%)、眼外肌受累(36.8%)、睑部受累(21.1%)、视神经受累(10.5%)、眶骨受累(10.5%)以及单神经炎(V1和/或V2,10.5%)。57.9%的病例中IgG4-ROD为双侧受累。78.9%的病例有眼外表现。所有患者对泼尼松均有反应,但三分之二的患者在平均(标准差)9.8(3.5)个月内复发,72.2%的患者需要长期使用糖皮质激素和/或免疫抑制剂。8例患者接受了利妥昔单抗治疗,87.5%的病例反应良好。
泪腺受累是IgG4-RD最常见的眼部表现,且常伴有眶外表现。尽管对类固醇治疗最初反应良好,但复发患者的长期管理仍需改进。